Targeting erbB receptors

Seminars in Cell and Developmental Biology

Volumn 21, Issue 9, 2010, Pages 961-966

  Cai, Zheng ^a   Zhang, Hongtao ^a   Liu, Jing ^b   Berezov, Alan ^c   Murali, Ramachandran ^c   Wang, Qiang ^c   Greene, Mark I ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

ErbB receptors; Monoclonal antibody; Peptide mimetic; Recombinant protein; Targeted therapy

Indexed keywords

ANTIEPIDERMAL GROWTH FACTOR RECEPTOR 2 PEPTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; LAPATINIB; MONOCLONAL ANTIBODY; PEPTIDOMIMETIC AGENT; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BIOLOGICAL ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; DIMERIZATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; MOLECULAR MIMICRY; NONHUMAN; PROTEIN FAMILY; PROTEIN TARGETING; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 78449272644     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2010.09.005     Document Type: Review

References (59)

1. Wen X.F., Yang G., Mao W., Thornton A., Liu J., Bast R.C., et al. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 2006, 25(52):6986-6996.
2. De Luca A., Carotenuto A., Rachiglio A., Gallo M., Maiello M.R., Aldinucci D., et al. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 2008, 214(3):559-567.
3. Drebin J.A., Link V.C., Greene M.I. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene 1988, 2(3):273-277.
4. Zhang H, Wang Q., Montone K.T., Peavey J.E., Drebin J.A., Greene M.I., et al. Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies. Oncogene 1999, 67(1):15-25.
5. Hu S., Zhu Z., Li L., Chang L., Li W., Cheng L., et al. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: molecular basis for tumor inhibitory mechanism. Proteins 2008, 70(3):938-949.
6. Furuuchi K., Berezov A., Kumagai T., Greene M.I. Targeted antireceptor therapy with monoclonal antibodies leads to the formation of inactivated tetrameric forms of ErbB receptors. J Immunol 2007, 178(2):1021-1029.
7. Maynard J., Georgiou G. Antibody engineering. Annu Rev Biomed Eng 2000, 2339-2376.
8. Hudson P.J., Souriau C. Engineered antibodies. Nat Med 2003, 9(1):129-134.
9. Reff M.E., Heard C. A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Crit Rev Oncol Hematol 2001, 40(1):25-35.
10. Bhat T.N., Bentley G.A., Boulot G., Greene M.I., Tello D., Dall'Acqua W., et al. Bound water molecules and conformational stabilization help mediate an antigen-antibody association. Proc Natl Acad Sci U S A 1994, 91(3):1089-1093.
11. Bruck C., Co M.S., Slaoui M., Gaulton G.N., Smith T., Fields B.N., et al. Nucleic acid sequence of an internal image-bearing monoclonal anti-idiotype and its comparison to the sequence of the external antigen. Proc Natl Acad Sci U S A 1986, 83(17):6578-6582.
12. Williams W.V., Moss D.A., Kieber-Emmons T., Cohen J.A., Myers J.N., Weiner D.B., et al. Development of biologically active peptides based on antibody structure. Proc Natl Acad Sci U S A 1989, 86(14):5537-5541.
13. Williams W.V., Kieber-Emmons T., VonFeldt J., Greene M.I., Weiner D.B. Design of bioactive peptides based on antibody hypervariable region structures. Development of conformationally constrained and dimeric peptides with enhanced affinity. J Biol Chem 1991, 266(8):5182-5190.
14. Dougall W.C., Peterson N.C., Greene M.I. Antibody-structure-based design of pharmacological agents. Trends Biotechnol 1994, 12(9):372-379.
15. Saragovi H.U., Fitzpatrick D., Raktabutr A., Nakanishi H., Kahn M., Greene M.I. Design and synthesis of a mimetic from an antibody complementarity-determining region. Science 1991, 253(5021):792-795.
16. Murali R., Greene M.I. Structure-based design of immunologically active therapeutic peptides. Immunol Res 1998, 17(1-2):163-169.
17. Park B.W., Zhang H.T., Wu C., Berezov A., Zhang X., Dua R., et al. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat Biotechnol 2000, 18(2):194-198.
18. Berezov A., Zhang H.T., Greene M.I., Murali R. Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis. J Med Chem 2001, 44(16):2565-2574.
19. Guillemard V., Nedev H.N., Berezov A., Murali R., Saragovi H.U. HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand. DNA Cell Biol 2005, 24(6):350-358.
20. Masuda K., Richter M., Song X., Berezov A., Masuda K., Murali R., et al. AHNP-streptavidin: a tetrameric bacterially produced antibody surrogate fusion protein against p185her2/neu. Oncogene 2006, 25(59):7740-7746.
21. Rosebrough S.F. Pharmacokinetics and biodistribution of radiolabeled avidin, streptavidin and biotin. Nucl Med Biol 1993, 20(5):663-668.
22. Zhang H., Cheng X., Richter M., Greene M.I. A sensitive and high-throughput assay to detect low-abundance proteins in serum. Nat Med 2006, 12(4):473-477.
23. Weiner D.B., Kokai Y., Wada T., Cohen J.A., Williams W.V., Greene M.I. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein. Oncogene 1989, 4(10):1175-1183.
24. Wada T., Qian X.L., Greene M.I. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 1990, 61(7):1339-1347.
25. Kokai Y., Myers J.N., Wada T., Brown V.I., LeVea C.M., Davis J.G., et al. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 1989, 58(2):287-292.
26. Stern D.F., Kamps M.P. EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions. EMBO J 1988, 7(4):995-1001.
27. Hackel P.O., Zwick E., Prenzel N., Ullrich A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 1999, 11(2):184-189.
28. Zwick E., Hackel P.O., Prenzel N., Ullrich A. The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol Sci 1999, 20(10):408-412.
29. Cooper J.A., Howell B. The when and how of Src regulation. Cell 1993, 73(6):1051-1054.
30. Biscardi J.S., Maa M.C., Tice D.A., Cox M.E., Leu T.H., Parsons S.J. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 1999, 274(12):8335-8343.
31. Emlet D.R., Moscatello D.K., Ludlow L.B., Wong A.J. Subsets of epidermal growth factor receptors during activation and endocytosis. J Biol Chem 1997, 272(7):4079-4086.
32. Levkowitz G., Waterman H., Ettenberg S.A., Katz M., Tsygankov A.Y., Alroy I., et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 1999, 4(6):1029-1040.
33. Ettenberg S.A., Keane M.M., Nau M.M., Frankel M., Wang L.M., Pierce J.H., et al. cbl-b inhibits epidermal growth factor receptor signaling. Oncogene 1999, 18(10):1855-1866.
34. Rojas M., Yao S., Lin Y.Z. Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. J Biol Chem 1996, 271(44):27456-27461.
35. Qian X., LeVea C.M., Freeman J.K., Dougall W.C., Greene M.I. Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. Proc Natl Acad Sci U S A 1994, 91(4):1500-1504.
36. Alimandi M., Romano A., Curia M.C., Muraro R., Fedi P., Aaronson S.A., et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995, 10(9):1813-1821.
37. Cohen B.D., Kiener P.A., Green J.M., Foy L., Fell H.P., Zhang K. The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. J Biol Chem 1996, 271(48):30897-30903.
38. Cohen B.D., Green J.M., Foy L., Fell H.P. HER4-mediated biological and biochemical properties in NIH 3T3 cells. Evidence for HER1-HER4 heterodimers. J Biol Chem 1996, 271(9):4813-4818.
39. Wallasch C., Weiss F.U., Niederfellner G., Jallal B., Issing W., Ullrich A. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 1995, 14(17):4267-4275.
40. Zhang K., Sun J., Liu N., Wen D., Chang D., Thomason A., et al. Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J Biol Chem 1996, 271(7):3884-3890.
41. Klapper L.N., Glathe S., Vaisman N., Hynes N.E., Andrews G.C., Sela M., et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A 1999, 96(9):4995-5000.
42. Carraway K.L., Cantley L.C. A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 1994, 78(1):5-8.
43. Peczuh M.W., Hamilton A.D. Peptide and protein recognition by designed molecules. Chem Rev 2000, 100(7):2479-2494.
44. Zutshi R., Brickner M., Chmielewski J. Inhibiting the assembly of protein-protein interfaces. Curr Opin Chem Biol 1998, 2(1):62-66.
45. Schramm H.J., Boetzel J., Büttner J., Fritsche E., Göhring W., Jaeger E., et al. The inhibition of human immunodeficiency virus proteases by 'interface peptides'. Antiviral Res 1996, 30(2-3):155-170.
46. Divita G., Restle T., Goody R.S., Chermann J.C., Baillon J.G. Inhibition of human immunodeficiency virus type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain. J Biol Chem 1994, 269(18):13080-13083.
47. Dutia B.M., Frame M.C., Subak-Sharpe J.H., Clark W.N., Marsden H.S. Specific inhibition of herpesvirus ribonucleotide reductase by synthetic peptides. Nature 1986, 321(6068):439-441.
48. Berezov A., Chen J., Liu Q., Zhang H.T., Greene M.I., Murali R. Disabling receptor ensembles with rationally designed interface peptidomimetics. J Biol Chem 2002, 277(31):28330-28339.
49. Qian X., Dougall W.C., Fei Z., Greene M.I. Intermolecular association and trans-phosphorylation of different neu-kinase forms permit SH2-dependent signaling and oncogenic transformation. Oncogene 1995, 10(1):211-219.
50. Qian X., O'Rourke D.M., Zhao H., Greene M.I. Inhibition of p185neu kinase activity and cellular transformation by co-expression of a truncated neu protein. Oncogene 1996, 13(10):2149-2157.
51. O'Rourke D.M., Qian X., Zhang H.T., Davis J.G., Nute E., Meinkoth J., et al. Trans receptor inhibition of human glioblastoma cells by erbB family ectodomains. Proc Natl Acad Sci U S A 1997, 94(7):3250-3255.
52. Stamos J., Sliwkowski M.X., Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002, 277(48):46265-46272.
53. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101(36):13306-13311.
54. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139.
55. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
56. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2(3):e73.
57. Wissner A., Mansour T.S. The development of HKI-272 and related compounds for the treatment of cancer. Arch Pharm (Weinheim) 2008, 341(8):465-477.
58. Li D., Shimamura T., Ji H., Chen L., Haringsma H.J., McNamara K., et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007, 12(1):81-93.
59. Scaltriti M., Verma C., Guzman M., Jimenez J., Parra J.L., Pedersen K., et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009, 28(6):803-814.